In the ALCHEMIST-ECOG-ACRIN platform A081105 and EA5142 trials, patients with resected stage IB (≥4 cm) to IIIA (AJCC 7th Ed) NSCLC harboring either EGFR or ALK alterations were assigned adjuvant erlotinib or crizotinib (versus observation), respectively [54]. This evidence concerns the gene ALK and non-small cell lung carcinoma.